| Basics |
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
|
| IPO Date: |
June 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.26B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.44 | 2.67%
|
| Avg Daily Range (30 D): |
$0.32 | 1.32%
|
| Avg Daily Range (90 D): |
$0.39 | 1.87%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.2M |
| Avg Daily Volume (30 D): |
1.49M |
| Avg Daily Volume (90 D): |
1.66M |
| Trade Size |
| Avg Trade Size (Sh.): |
130 |
| Avg Trade Size (Sh.) (30 D): |
69 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Inst.Trades: |
9,853 |
| Avg Inst. Trade: |
$2.27M |
| Avg Inst. Trade (30 D): |
$3.71M |
| Avg Inst. Trade (90 D): |
$3.63M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.1M |
| Avg Closing Trade (30 D): |
$6.39M |
| Avg Closing Trade (90 D): |
$6.74M |
| Avg Closing Volume: |
170.49K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$.16
|
$.11
|
|
Diluted EPS
|
|
$.16
|
$.11
|
|
Revenue
|
$
|
$ 264.57M
|
$ 244.32M
|
|
Gross Profit
|
$
|
$ 243.83M
|
$ 223.93M
|
|
Net Income / Loss
|
$
|
$ 26.67M
|
$ 18.99M
|
|
Operating Income / Loss
|
$
|
$ 32.37M
|
$ 19.29M
|
|
Cost of Revenue
|
$
|
$ 20.73M
|
$ 20.39M
|
|
Net Cash Flow
|
$
|
$ 36.62M
|
$ -101.89M
|
|
PE Ratio
|
|
|
|
|
|
|
